作者: Mark A. Rubin , Himisha Beltran
DOI:
关键词:
摘要: Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one AURKA MYCN define a distinct subgroup cancer is predisposed to development lethal NEPC, who will benefit from early intervention.